Recent Innovations in Alzheimer’s Disease Care: Advances in Diagnostics, Therapy, and AI Caregiver Support

Introduction

Alzheimer’s disease is a progressive neurodegenerative disorder that affects an estimated 6.9 million Americans today, a figure expected to rise significantly with population aging [1]. As the most common cause of dementia, Alzheimer’s is a leading contributor to disability and dependency among older adults, placing an immense burden, both mental and fiscal, on patients, families, and healthcare systems. In 2023, over 11 million informal and unpaid caregivers in the U.S. provided 18.4 billion hours of care, valued at $346.6 billion [1]. The complex demands of Alzheimer’s care often lead to caregiver burnout, impacting emotional, physical, and financial well-being [1].

Over the past five years, advancements in diagnostics, therapies, and artificial intelligence (AI) driven caregiver support have garnered substantial attention and led to innovation in comprehensive management of Alzheimer’s disease. Although these developments have transformed aspects of Alzheimer’s care, the underlying pathology remains defined by the accumulation of amyloid-β plaques and tau neurofibrillary tangles [1, 2, 3, 4, 5]. This pathology disrupts neural communication and triggers widespread neuroinflammation, leading to brain tissue deterioration and cognitive decline [1, 2]. Recent advances in diagnostics, especially in blood-based biomarkers, offer more accessible and precise tools for timely interventions. As for therapies, recent efforts have shifted towards disease-modifying treatments targeting amyloid-β after several clinical trials found evidence supporting that plaque removal improved cognition [2, 3, 4, 5]. However, the impact is highly debated due to mixed clinical outcomes and the heterogeneity of Alzheimer’s pathology [6, 7]. Simultaneously, AI-driven caregiver support has emerged as a unique innovation addressing the caregiving burden. Numerous AI tools are now available to coordinate care and support caregivers’ well-being [8, 9, 10, 11]. By alleviating caregiver burnout, these technologies ensure more sustainable care for individuals with Alzheimer's. This review will focus on these three rapidly evolving areas― advancements in diagnostics, therapies, and caregiver support― to reflect a comprehensive approach to improving patient outcomes and strengthening caregiver support.

Advancements in Diagnostics 

Diagnostics are essential to detect Alzheimer's disease, monitor progression, and evaluate drug effectiveness [12,13]. Early and precise detection not only facilitates timely intervention but also alleviates uncertainty and stress for caregivers. A pivotal development in Alzheimer’s research is the AT(N) framework introduced by the National Institute of Aging and Alzheimer’s Association in 2018 [12]. This framework provides a structured system for organizing individuals’ Alzheimer’s disease pathology across three domains: amyloid-β plaques (A), tau neurofibrillary tangles (T), and neurodegeneration biomarkers (N). Each biomarker is classified as either positive or negative, allowing clinicians and researchers to identify where a patient falls along the disease continuum. For example, individuals in the preclinical phase, who have amyloid-β accumulation without tau or neurodegeneration, would be designated as A+T-N-. Whereas those in symptomatic stages, showing abnormalities in all three domains, would be A+T+N+. This standardized and biologically grounded system promotes consistency in clinical diagnostics and helps stratify participants in clinical trials. However, comorbidities, like cerebrovascular disease or epilepsy, can influence these biomarkers and complicate diagnosis [1]. In these cases, a comprehensive evaluation is needed [1].

Recent advancements in blood-based biomarkers offer minimally invasive and cost-effective diagnostic tools. Plasma p-tau217, a phosphorylated tau isoform, has emerged as a promising biomarker correlating strongly with the costly positron emission tomography (PET) scans in distinguishing Alzheimer’s from non-Alzheimer’s tauopathies [14, 15]. To compare the performance of diagnostic tests, studies measured the area under the curve (AUC). AUC reflects the ability to discriminate between individuals with and without a condition, with an AUC of 1.0 indicating that the test has perfect sensitivity and specificity. The AUC of p-tau217 blood assay is 0.93 and 0.87 for tau-PET and amyloid β-PET scans respectively with 95% confidence intervals [14, 15]. In other words, p-tau217 correctly identified 93% of Alzheimer’s cases confirmed by tau-PET and 87% of cases by amyloid-β-PET scans [14, 15]. Furthermore, p-tau217 can predict individuals who develop Alzheimer’s or progress in disease severity [15]. Higher p-tau217 levels were observed in individuals with high likelihood of AD, as indicated by neuritic plaques [15]. Moreover, the cost differential is substantial. The average PET scan costs $5,000, whereas p-tau217 blood assays cost $194. This highlights p-tau217 as a crucial blood biomarker for early intervention, trial participant selection, and potential medication validity [14, 15].

Despite its potential, p-tau217 has limitations. Elevated p-tau217 levels have been observed in individuals with lower BMI, hypertension, and females with PSEN1 mutation [16, 17, 18, 19]. This may obscure the relationship between p-tau217 and Alzheimer’s pathology, thus confound clinical data and diagnoses. Thus, other Alzheimer’s and non-Alzheimer’s diagnostics should also be taken in concert to diagnose a patient accurately.

Disease-Modifying Therapies 

Recent progress in disease-modifying therapies has shifted the focus toward targeting amyloid-β plaques in the brain [20]. Each drug operates through distinct mechanisms and targets different stages of amyloid-β accumulation to slow cognitive and functional decline [20]. In the last five years, several therapies have emerged and discontinued, reflecting the progress and ongoing challenges in targeting the underlying pathology of Alzheimer’s. This section examines three notable disease-modifying therapies― aducanumab, lecanemab, and donanemab― in order of their FDA approvals. These therapeutics are monoclonal antibodies targeting amyloid-β plaques in the brain and are administered intravenously every two to four weeks [2, 4, 5, 20, 21, 22]. Aducanumab binds to earlier forms of amyloid-β aggregates, including soluble oligomeric and insoluble fibrillar forms [2, 31]. Lecanemab targets protofibrils, which are aggregates of oligomers and considered to be the most toxic form of aggregates [22, 23]. Lastly, donanemab binds to amyloid plaques, or clumps of fibrils [4, 5].  Disease-modifying therapies offer a targeted approach to Alzheimer’s but raise concerns about long-term efficacy and safety.

Aducanumab, approved in 2021 through the FDA’s accelerated pathway, was the first therapy to demonstrate that amyloid-β removal can slow cognitive and functional decline in early Alzheimer’s [7, 20]. However, high-dose aducanumab was associated with amyloid-related imaging abnormalities (ARIA), a common side effect of anti-amyloid therapy [2, 6]. Although most ARIA cases do not lead to clinical symptoms, 10% of participants who experienced ARIA from aducanumab were symptomatic and experienced headache, confusion, dizziness, and nausea [2, 6]. Despite initial optimism, aducanumab was discontinued in November 2024 due to high costs, limited efficacy, and shifting priorities [15].

Next, lecanemab was approved by the FDA in 2023 [20, 23]. Clinical trials have shown that lecanemab significantly reduced amyloid-β plaques in a dose-dependent manner and correlated with slowed cognitive decline [5]. Remarkably, the benefits persisted even two years after discontinuation of the medication [5]. However, the long-term rate of Alzheimer’s progression in treated participants was similar to those who received a placebo [5]. Overall, participants experienced a higher risk of infusion-related reactions during drug administration.

Lastly, donanemab was recently approved by the FDA in 2024 [20]. Donanemab reduced amyloid-β plaques less effectively than lecanemab but slowed cognitive and functional decline better, as measured by a smaller reduction in the Integrated Alzheimer’s Disease Rating Scale [4]. This scale assesses cognitive abilities and activities of daily function, providing a comprehensive measure of Alzheimer’s-related impairment [4]. While donanemab rapidly reduced amyloid-β levels and even led to complete amyloid clearance in some participants, clinical outcomes varied [4, 5, 24]. Additionally, participants faced a higher risk of ARIA compared to lecanemab.

Despite the potential of these therapies, the efficacy and safety of anti-amyloid therapies remain a topic of debate. Many studies demonstrated that removing amyloid plaques successfully slowed cognitive and functional decline in early Alzheimer’s [2, 3, 4, 5, 22]. However, some studies found limited clinical improvements [21, 24, 25]. One study suggested that these results may have been influenced by small sample sizes or the broad inclusion of participants from mild cognitive impairment to moderate Alzheimer’s stage [24]. Furthermore, all three therapies― aducanumab, lecanemab, and donanemab― carry the risk of ARIA, which may lead to adverse symptoms and intolerance [2, 4, 6, 22, 24]. A recent meta-analysis concluded no significant differences in cognitive and functional outcomes between aducanumab, lecanemab, and donanemab, highlighting the need for continued research and innovation in Alzheimer’s treatment [7].

AI in Caregiving 

While clinical advancements are improving the lives of individuals with Alzheimer’s disease, caregivers still play an integral role. They help manage daily activities, assist with decision-making, and monitor progress. However, caregiving places immense emotional, physical, and financial strain on family members and loved ones [1]. In 2022, over 11 million caregivers in the U.S. provided an estimated 18.4 billion hours of unpaid care, underscoring the urgent need for comprehensive support systems [1, 26]. Recent advances in artificial intelligence (AI) and technology have emerged as promising solutions by supporting practical caregiving tasks and mental well-being.

AI-driven tools are revolutionizing daily caregiving. AI can support caregivers by answering questions, supporting daily tasks, simplifying meal planning, and improving their mental health. Numerous virtual care assistant programs and apps are available or being developed. The Elevmi app, launched in October 2024, is a free digital assistant designed to guide caregivers throughout their journey [27]. Its 4.8-star rating on the Apple App Store reflects strong early user satisfaction. The app helps track behavioral changes, prepares reports for doctor visits, and delivers personalized guidance from the National Institute of Aging and other reliable resources [27]. Another tool is Sensi AI [28]. Sensi AI was launched in 2019 as a 24/7 assistant monitoring daily routines, safety risks, and early signs of cognitive decline to ensure safety and caregivers’ peace of mind [28]. AI-driven platforms also assist in nutrition management, a critical part of Alzheimer's care. AI meal planning systems often promote the Mediterranean-DASH diet, which is known to slow cognitive decline and reduce Alzheimer's risk [10, 29]. These tools personalize meal recommendations based on patients’ preferences, culture, and practical constraints such as time and budget [10, 29]. These technologies ease the burden of decision-making, making it more manageable for caregivers to meet dietary needs and evidence-based recommendations. In addition, several robots have been developed to assist caregivers [8, 30]. One of these is the Robot-based Information and Support (RISE), a project that recently received funding in October 2024 [8]. RISE aims to develop an AI humanoid social robot that offers individualized training and stress management for caregivers through interactive modules [8].

In parallel, AI has been used to improve caregivers’ emotional well-being. The Elevmi app checks in with caregivers monthly and offers an AI bot named “Elle” for real-time emotional support [27]. Many users agreed that Elle’s compassionate tone provides comfort during difficult moments. Other apps focus on mentalizing imagery therapy to provide guided mindfulness exercises and stress-relieving visualization techniques [11]. Caregivers using the app reported better emotional resilience and the ability to reframe the caregiver experience [11]. Meanwhile, other researchers are developing a prototype interactive system that uses voice-monitoring technology to detect caregiver stress and emotional tension [9, 31]. By analyzing tone, pitch, and other vocal patterns, the system provides real-time suggestions to promote relaxation [9, 31]. Caregivers who tried the demo report feeling more calm, in control, and better equipped to manage caregiving challenges [9, 31]. While these tools show promising potential, there are limitations. Some users report that the AI chatbots can be “glitchy” or fail to retain previously shared information, which affects their ability to provide consistent support [27]. Moreover, despite adherence to HIPAA and other regulatory guidelines, privacy concerns remain. AI-driven tools collect data to enhance the personalization of their services, but this introduces the risk of potential sensitive data breaches. As AI continues to evolve, user feedback and strong data security will be essential. Together, these innovations have the potential to provide comprehensive support and promote the well-being of caregivers and individuals with Alzheimer’s.

Conclusion

Alzheimer's disease care has made notable strides in diagnostics, therapies, and AI-driven caregiver support in the last five years. Blood-based biomarkers like p-tau217 show promise for early detection, timely interventions, and personalized care. Meanwhile, therapies like aducanumab, lecanemab, and donanemab highlight progress in targeting amyloid-β plaques, though concerns remain about their long-term efficacy and safety. These treatments show promise but underscore the need for continued research and refinement. Equally important are AI-driven tools that alleviate the burden on caregivers. Digital assistants, meal planning tools, and mental well-being apps provide practical and emotional support. By offering personalized guidance, these technologies empower caregivers and improve the quality of care. Together, these advancements represent a comprehensive approach to Alzheimer's care. Continued innovation and interdisciplinary collaboration will be vital to improve outcomes for individuals with Alzheimer's and their families.

Author’s Note

I originally wrote this piece for my  HDE117 Longevity Course term paper, but revisited it recently to update it. Since I finished that course, I have been volunteering at a local hospice where I work closely with individuals who have Alzheimer’s/other forms of dementia and their caregivers. Whether it’s preparing meals that meet individual dietary needs and preferences, assisting with enrichment activities, or supporting overwhelmed caregivers, I experienced firsthand how tailored care can improve their quality of life. This experience has provided me with a deeper understanding of the challenges associated with Alzheimer's, and I wanted to revise my paper to make it more relevant and impactful today. Additionally, Dr. Carey has kindly offered to mentor me through the revision process to ensure it aligns with current standards and reflects the latest research.

I chose this topic because Alzheimer’s is more than just a medical condition. It affects families, caregivers, and entire support networks. After reading about recent developments in Alzheimer’s care, three topics stood out to me in terms of addressing critical challenges and the ongoing timeline in Alzheimer’s care― advancements in diagnostics, therapies, and AI-driven caregiver support. Advancements in diagnostics are paving the way for earlier and more accurate detection, which is crucial for timely intervention. This allows emerging therapies to target different mechanisms to slow disease progression and improve patients’ quality of life. Finally, innovations in AI show promise in personalizing support for patients and caregivers alike. Together, these three areas show great promise in improving care and outcomes for those affected by Alzheimer’s and their loved ones. 

My goal is for readers to walk away with a deeper understanding of the latest innovations in Alzheimer’s care and a new perspective on how we can support individuals living with Alzheimer’s. I hope this piece inspires greater awareness and support for Alzheimer’s care.

References

1. 2024 Alzheimer's disease facts and figures. (2024). Alzheimer's & dementia : the journal of the Alzheimer's Association, 20(5), 3708–3821. https://doi.org/10.1002/alz.13809
2. Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O'Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H. M., Engber, T., … Sandrock, A. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature, 537(7618), 50–56. https://doi.org/10.1038/nature19323
3. McDade, E., Cummings, J. L., Dhadda, S., Swanson, C. J., Reyderman, L., Kanekiyo, M., ... & Bateman, R. J. (2022). Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimer's research & therapy, 14(1), 191.
4. Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., ... & Skovronsky, D. M. (2021). Donanemab in early Alzheimer’s disease. New England Journal of Medicine, 384(18), 1691-1704.
5. Shcherbinin, S., Andersen, S. W., Evans, C. D., Lo, A. C., Lu, M., Navitsky, M., ... & Mintun, M. A. (2021). TRAILBLAZER‐ALZ Study: Dynamics of amyloid reduction after donanemab treatment. Alzheimer's & Dementia, 17, e057492.
6. Salloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., ... & Smirnakis, K. (2022). Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA neurology, 79(1), 13-21.
7. Terao, I., & Kodama, W. (2024). Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: a systematic review and network meta-analysis. Ageing Research Reviews, 102203.
8. News Medical. (2024, October 21). News-Medical. News-Medical. https://www.news-medical.net/news/20241020/New-AI-powered-robot-project-to-support-Alzheimers-caregivers.aspx
9. Gao, Y., Salekin, A., Gordon, K., Rose, K., Wang, H., & Stankovic, J. (2021). Emotion recognition robust to indoor environmental distortions and non-targeted emotions using out-of-distribution detection. ACM Transactions on Computing for Healthcare (HEALTH), 3(2), 1-22.
10. Amiri, M., Li, J., & Roy, S. (2022). Meal Planning for Alzheimer's Disease Using an Ontology-Assisted Multiple Criteria Decision-Making Approach. International Journal of E-Health and Medical Communications (IJEHMC), 13(1), 1-14.
11. Sikder, A. T., Yang, F. C., Schafer, R., Dowling, G. A., Traeger, L., & Jain, F. A. (2019). Mentalizing imagery therapy mobile app to enhance the mood of family dementia caregivers: feasibility and limited efficacy testing. JMIR aging, 2(1), e12850.
12. Jack, C. R., Jr, Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., Liu, E., Molinuevo, J. L., Montine, T., Phelps, C., Rankin, K. P., Rowe, C. C., Scheltens, P., Siemers, E., Snyder, H. M., Sperling, R., … Contributors (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 14(4), 535–562. https://doi.org/10.1016/j.jalz.2018.02.018
13. Barthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., Li, Y., La Joie, R., Benzinger, T. L. S., Morris, J. C., Mattsson-Carlgren, N., Palmqvist, S., Ossenkoppele, R., Rabinovici, G. D., Stomrud, E., Bateman, R. J., … Hansson, O. (2024). Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests. Nature medicine, 30(4), 1085–1095. https://doi.org/10.1038/s41591-024-02869-z
14. Wennström, M., Janelidze, S., Nilsson, K. P. R., Netherlands Brain Bank, Serrano, G. E., Beach, T. G., Dage, J. L., & Hansson, O. (2022). Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels. Acta neuropathologica communications, 10(1), 3. https://doi.org/10.1186/s40478-021-01307-2
15. Shcherbinin, S., Evans, C. D., Lu, M., Andersen, S. W., Pontecorvo, M. J., Willis, B. A., Gueorguieva, I., Hauck, P. M., Brooks, D. A., Mintun, M. A., & Sims, J. R. (2022). Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA neurology, 79(10), 1015–1024. https://doi.org/10.1001/jamaneurol.2022.2793
16. Pichet Binette, A., Janelidze, S., Cullen, N., Dage, J. L., Bateman, R. J., Zetterberg, H., Blennow, K., Stomrud, E., Mattsson-Carlgren, N., & Hansson, O. (2023). Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance. Alzheimer's & dementia : the journal of the Alzheimer's Association, 19(4), 1403–1414. https://doi.org/10.1002/alz.12787
17. Mielke, M. M., Dage, J. L., Frank, R. D., Algeciras-Schimnich, A., Knopman, D. S., Lowe, V. J., Bu, G., Vemuri, P., Graff-Radford, J., Jack, C. R., Jr, & Petersen, R. C. (2022). Performance of plasma phosphorylated tau 181 and 217 in the community. Nature medicine, 28(7), 1398–1405. https://doi.org/10.1038/s41591-022-01822-2
18. Vila-Castelar, C., Chen, Y., Langella, S., Lopera, F., Zetterberg, H., Hansson, O., Dage, J. L., Janelidzde, S., Su, Y., Chen, K., Pluim McDowell, C., Martinez, J. E., Ramirez-Gomez, L., Garcia, G., Aguillon, D., Baena, A., Giraldo-Chica, M., Protas, H. D., Ghisays, V., Rios-Romenets, S., … Quiroz, Y. T. (2023). Sex differences in blood biomarkers and cognitive performance in individuals with autosomal dominant Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 19(9), 4127–4138. https://doi.org/10.1002/alz.13314
19. O'Bryant, S. E., Petersen, M., Hall, J., Johnson, L. A., & HABS-HD Study Team (2023). Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice. Alzheimer's & dementia : the journal of the Alzheimer's Association, 19(1), 36–43. https://doi.org/10.1002/alz.12647
20. FDA-approved treatments for Alzheimer’s. (n.d.). https://www.alz.org/media/documents/alzheimers-dementia-fda-approved-treatments-for-alzheimers-ts.pdf
21. Alzheimer's Association. (2024). Aducanumab Approved for Treatment of Alzheimer’s Disease. Alzheimer’s Disease and Dementia. https://www.alz.org/alzheimers-dementia/treatments/aducanumab
22. Lannfelt, L., Söderberg, L., Laudon, H., Sahlin, C., Johannesson, M., Nygren, P., & Möller, C. (2019, July). BAN2401 shows stronger binding to soluble aggregated amyloid-beta species than aducanumab. In BioArctic poster presentation. Alzheimer’s Association International Conference (pp. 14-18).
23. Van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., ... & Iwatsubo, T. (2023). Lecanemab in early Alzheimer’s disease. New England Journal of Medicine, 388(1), 9-21.
24. Lowe, S. L., Duggan Evans, C., Shcherbinin, S., Cheng, Y. J., Willis, B. A., Gueorguieva, I., ... & AACD Investigators. (2021). Donanemab (LY3002813) phase 1b study in Alzheimer’s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. The journal of prevention of Alzheimer's disease, 8, 414-424.
25. Lythgoe, M. P., Jenei, K., & Prasad, V. (2022). Regulatory decisions diverge over aducanumab for Alzheimer’s disease. Bmj, 376.
26. Better, M. A. (2023). Alzheimer’s disease facts and figures. Alzheimers Dement, 19(4), 1598-1695.
27. (2024). Elevmi.com. https://elevmi.com/
28. Sensi. (n.d.). Sensi. https://www.sensi.ai/
29. Li, J., Maharjan, B., Xie, B., & Tao, C. (2020). A personalized voice-based diet assistant for caregivers of Alzheimer disease and related dementias: system development and validation. Journal of Medical Internet Research, 22(9), e19897.
30. Yuan, F., Bowland, S., Proctor, L., Blackburn, J., Mukherjee, N., Bray, R., ... & Zhao, X. (2022, November). Robot-assisted psycho-education to enhance Alzheimer’s caregiver health. In 2022 IEEE/ACM Conference on Connected Health: Applications, Systems and Engineering Technologies (CHASE) (pp. 57-65). IEEE.
31. Gao, Y., Ma, M., Gordon, K., Rose, K., Wang, H., & Stankovic, J. (2020, November). A monitoring, modeling, and interactive recommendation system for in-home caregivers: Demo abstract. In Proceedings of the 18th Conference on Embedded Networked Sensor Systems (pp. 587-588).
32. Taylor, E. (2023, May 4). New Alzheimer’s drug, donanemab – what is it and how does it work? Alzheimer’s Research UK. https://www.alzheimersresearchuk.org/news/new-alzheimers-drug-donanemab-what-is-it-and-how-does-it-work/